Microsatellite-stable BRAF-mutated metastatic colorectal cancer patients treated with anti-EGFR/BRAF combinations had better responses and survival outcomes when RNF43 was mutated compared with wild-type cases. This evidence concerns the gene EGFR and metastatic colorectal cancer.